title: Update on overactive bladder: pharmacologic approaches on the horizon.
abstract: Limitations exist with regard to the array of available agents for the pharmacologic therapy of overactive bladder, including issues of efficacy and tolerability. It is clear that the ideal agent for this condition has not been identified. However, several new pharmacologic treatments, including some with novel approaches to drug delivery, have emerged in clinical development over the past few years. These agents include a variety of anticholinergics and others. In initial studies, some of the agents appear to compare favorably with existing therapies. Whether these promising results will hold up when subjected to large-scale, well-controlled clinical trials is unclear.
mesh_terms: D000279:Administration, Cutaneous; D000283:Administration, Intravesical; D000284:Administration, Oral; D058673:Adrenergic beta-3 Receptor Antagonists; D001559:Benzhydryl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics; D001561:Benzilates; D001572:Benzofurans / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D003408:Cresols / Q000008:administration & dosage / Q000493:pharmacokinetics; D004304:Dosage Forms; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding / Q000379:methods; D004341:Drug Evaluation / Q000379:methods; D000068736:Duloxetine Hydrochloride; D006801:Humans; D008333:Mandelic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics; D018727:Muscarinic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D009662:Nortropanes / Q000627:therapeutic use; D010665:Phenylpropanolamine; D011759:Pyrrolidines / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D001745:Urinary Bladder Diseases / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000150:complications / Q000188:drug therapy*
chemical_list: D058673:Adrenergic beta-3 Receptor Antagonists; D001559:Benzhydryl Compounds; D001561:Benzilates; D001572:Benzofurans; D003408:Cresols; D004304:Dosage Forms; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D009662:Nortropanes; D011759:Pyrrolidines; D013876:Thiophenes; C003330:trospium chloride; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate; D000068736:Duloxetine Hydrochloride; C101207:darifenacin; D001905:Botulinum Toxins; C005419:oxybutynin